The Glaxo worldwide system for monitoring the safety profile of its marketed and investigational products is described. This paper specifically focuses on the coordinated development of drug surveillance activities between Glaxo Group Research (United Kingdom) and Glaxo Inc. (United States). Central to this dedicated effort is a single worldwide computer system for the storage, monitoring and retrieval of adverse event data.
